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We retrospectively investigated the efficacy and feasibility of concurrent chemoradiotherapy for patients with severe dysphagia
caused by oesophageal squamous cell carcinoma. Concurrent chemoradiotherapy was performed in 57 patients with T3 or T4
disease containing M1 lymph node (LYM) disease. Chemotherapy consisted of protracted infusion of 5-fluorouracil (5-FU)
400mgm
 224h
 1 on days 1–5 and 8–12, combined with 2-h infusion of cisplatin (CDDP) 40mgm
 2 on days 1 and 8. Radiation
treatment at a dose of 30Gy in 15 fractions of the mediastinum was administered concomitantly with chemotherapy. A course
schedule with 3-week treatment and a 1 to 2-week break was applied twice, with a total radiation dose of 60Gy, followed by two or
more courses of 5-FU and CDDP. In all, 24 patients (42%) achieved a complete response, and the 3-year survival rate was 19%.
Major toxicities were leukocytopenia and oesophagitis, and there were two (4%) treatment-related deaths. In contrast, 22 patients
with T3 disease survived longer than 35 patients with T4 disease (P¼0.001); however, the survival rate in 15 patients with M1 LYM
disease did not differ significantly from that in 42 patients without M1 LYM disease (P¼0.3545). Our results indicate that definitive
chemoradiotherapy is potentially curative for locally advanced oesophageal carcinoma with malignant stricture. The efficacy and
survival of patients treated with this regimen are related to the T factor.
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The indications for definitive chemoradiotherapy for patients with
severe dysphagia caused by oesophageal carcinoma are poorly
defined. Dysphagia is a major symptom that affects the quality of
life in patients with unresectable oesophageal tumours. Chemo-
therapy, radiotherapy, laser therapy, and stent insertion have been
reported to relieve symptoms. Recently, metallic stents have
become popular in the palliative treatment of patients with
dysphagia caused by oesophageal carcinoma (Song et al, 1991;
Bethge et al, 1992; Fleischer et al, 1992; Kozarek et al, 1992; Schaer
et al, 1992; Knyrim et al, 1993; May et al, 1995; Wengrower et al,
1998). These stents can be inserted on an outpatient basis and
provide rapid relief of symptoms of dysphagia. However, the
indications for metallic stent insertion in patient with severe
dysphagia caused by oesophageal carcinoma also remain con-
troversial, and the clinical staging has not been evaluated before
implantation of metallic stents in these reports.
On the other hand, the effects of chemotherapy combined with
radiotherapy on oesophageal carcinoma have been investigated
since the 1980s. Several investigators have reported successful
results with these modalities, either with or without surgery,
against local–regional carcinoma (Leichman et al, 1984; Leichman
et al, 1987; Poplin et al, 1987; Coia et al, 1991; Frorastiere et al,
1993; Poplin et al, 1994). The combination of 5-fluorouracil
(5-FU) and cisplatin (CDDP) has become a standard regimen,
not only because of the clinical outcome but also because of
the synergism between the two agents and their radiosensitising
effects (Douple et al, 1980; Scanlon et al, 1986; Byfield, 1990).
Recently published results on chemoradiotherapy indicated that it
offers various advantages for the treatment of carcinoma of the
oesophagus (Frorastiere et al, 1993; Coia, 1994). In a prospective
randomised trial by the Radiation Therapy Oncology Group,
which compared chemoradiotherapy with radiotherapy alone,
the combined-modality arm demonstrated a significant
improvement of survival (Herskovic et al, 1992), with a 5-year
survival rate of 27%, compared with 0% for radiotherapy alone
(Al-Sarraf et al, 1997). With regard to the indications of
chemoradiotherapy as a curative treatment for patients with
locally advanced diseases, our multicentre study suggested that
concurrent chemoradiotherapy was potentially curative even in
cases with locally advanced carcinoma of the oesophagus (i.e., T4
and/or M1 lymph node metastasis (LYM) disease) (Ohtsu et al,
1999). Of the 54 patients in that study, 18 (33%) achieved a
complete response, and the 3-year survival rate was 23%. On
the other hand, there are no studies that investigated the effects
of chemoradiotherapy in patients with oesophageal stricture
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symptom.
In the present retrospective study, we evaluated the effects of
chemoradiotherapy for patients with ‘malignant stricture’ caused
by squamous cell carcinoma of the oesophagus. Definition of
tumour stage was based on the 1987 criteria of the tumour-node-
metastasis (TNM) classification of the International Union Against
Cancer (UICC). Accordingly, T4 was defined as a tumour that
invaded contiguous structures and M1 LYM was defined as nodal
metastasis beyond the regional lymph nodes. The efficacy and
feasibility of chemoradiotherapy were analysed in consecutive
patients with malignant stricture caused by oesophageal squamous
cell carcinoma.
METHODS AND MATERIALS
Patient population
From May 1996 to March 2000, 70 consecutive patients aged p75
years were diagnosed at Showa University School of Medicine as
having locally advanced oesophageal carcinoma with malignant
stricture associated with severe dysphagia. Of the 70 patients, 13
were excluded from the present study for the presence of
malignant fistula (n¼1), distant metastasis (liver metastasis
(n¼4), lung metastasis (n¼2), bone metastasis (n¼3)), medical
conditions (including ineligible laboratory data as defined below,
n¼2), or concurrent gastric cancer (n¼1). None of the patients
had other malignancies or surgery and chemotherapy for previous
diseases. Previous studies indicated that 95% of oesophageal
cancers in Japanese patients are squamous cell carcinomas
(Japanese Research Society for Esophageal Diseases, 1997). In
agreement with that observation, none of the patients enrolled in
this study had oesophageal adenocarcinoma; thus, all patients had
squamous cell carcinoma of the oesophagus. All patients were
enrolled in the present study after registration in the previous
study (Ohtsu et al, 1999).
Eligibility criteria
Patients who were eligible for this trial had previously untreated,
histologically confirmed squamous cell carcinoma of the thoracic
oesophagus. The tumours had to show evidence of T3 and T4
disease, containing M1 LYM disease, based on the staging criteria
of the UICC. The prestudy clinical evaluation included air contrast
barium oesophagography, oesophagoscopy, neck computed tomo-
graphy (CT), chest CT, abdominal CT, endoscopic ultrasono-
graphy, bronchoscopy, and bone scan. However, endoscopic
ultrasonography was optional since the endoscope could not be
passed through stenotic lesions in most cases (89%). Broncho-
scopy was performed in some cases when tracheobronchial
involvement was suspected. Adjacent organs were considered to
be involved if the tumours extended into the oesophageal lumen,
caused deformity of the tracheobronchial tree or if the tumours
appeared to be attached to the organs at a 4901 angle to the
thoracic aorta as observed on the CT scan (Picus et al, 1983;
Takashima et al, 1991). T3 or a lesser extent of the disease was
determined by endoscopic ultrasonography. In those patients who
could not undergo this procedure, T3 was defined based on the
lack of any associated abnormal bronchoscopic findings; that is, no
deformity of the airway and tracheobronchial tree on the CT scan.
Furthermore, we modified the criteria described previously for the
definition of T3 disease (Picus et al, 1983) to include tumours
attached to the organs at a p901 angle to the thoracic aorta as
observed on the CT scan. The patients were considered to have
LYM if the tumour was X1cm in diameter (Curtin et al, 1998).
Radiological evaluations for staging were reviewed by two
radiologists (TK and YM) and the physicians at Showa University
School of Medicine, as was reported in previous studies (Picus et al,
1983; Takashima et al, 1991; Curtin et al, 1998). However, while the
UICC staging criteria were adopted in these previous studies, we
used a non-standard staging technique in this study, especially
when evaluating the depth of tumour infiltration. The clinical
staging was also evaluated according to 1983 AJCC staging criteria.
The following criteria were used for enrolment for chemoradio-
therapy: (1) An Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 2 or less, (2) satisfactory haematologic
function (leukocyte count X3000mm
 3 and platelet count
X100000mm
 3), (3) satisfactory hepatic function (AST or ALT
levels within three times the normal upper limit and a serum
bilirubin level of less than 2.0mgdl
 1), (4) good renal function
(creatinine level p1.5mgdl
 1 and creatinine clearance
X50mlmin
 1), (5) satisfactory pulmonary function (PaO2
X70mmHg), (6) normal electrocardiogram, and (7) life expec-
tancy X8 weeks. Patients with serious complications, such as a
history of ischaemic heart disease, pulmonary fibrosis, or active
carcinoma at another site were excluded from the study. After
explaining the true disease status and predicted complications of
the treatment, including the possibility of treatment-related death,
each patient gave informed consent for the study. The study
protocol was approved by the Human Ethics Review Committee of
Showa University School of Medicine.
Treatment schedule
Chemotherapy consisted of protracted infusion of 5-FU at a dose
of 400mgmday
 1 on days 1–5 and 8–12, combined with a 2-h
infusion of CDDP at 40mgm
 2 on days 1 and 8. A 10MV radiation
treatment was administered for 3 weeks (5 days/week) at
2Gyday
 1, concomitantly with chemotherapy. The targeted area
for carcinoma of the upper and middle thirds of the oesophagus
included the primary tumours with a 3-cm margin craniocaudally
and any metastatic nodes with 1- to 1.5-cm margin, in the
supraclavicular fossa and mediastinum. For carcinoma of the
lower third of the oesophagus, the field was extended to include the
perigastric nodes, while the supraclavicular fossa was excluded if
the cervical nodes were found to be negative. The daily fractional
dose of radiotherapy was 2Gy administered 5 days a week. When
the planned volume included both the supraclavicular fossa and
upper abdominal nodes, a daily dose of 1.8Gy was allowed. After a
dose of 30Gy, we allowed a 1- to 2-week treatment-free period.
Radiotherapy was restarted on day 29 or 36, along with the same
schedule of chemotherapy as described above. The treatment
course included 3 weeks of radiotherapy followed by a 1- to 2-week
break, and the 30Gy course was administered twice, with a total
radiation dose of 60Gy. The irradiation techniques were initially
applied in anterior and posterior opposed fields. At 40Gy, the
radiation portals were reduced to shield the spinal cord and to
encompass the primary tumour craniocaudally with a 2- to 3-cm
margin, usually by using an oblique opposed field. Metastatic
nodes were encompassed with a 1- to 1.5-cm margin. The total
radiation dose to the spinal cord was kept at a maximum of 40Gy.
The homogeneity of the dose within the planning volume was
within 710% of the prescribed dose.
Patients who were evaluated for an objective response to the
above treatment received additional chemotherapy consisting of a
continuous infusion of 5-FU at a dose of 800mgm
 2 on days 1–5
and CDDP at a dose of 80mgm
 2 on day 1. This treatment
schedule of 1-week treatment followed by a 3- to 4-week break was
only repeated once in some patients and no further treatment was
applied if no disease progression was observed. When a single
course consisted of treatment followed by a 45-week break, we
defined the latter as interruption. All patients receiving chemo-
radiotherapy were monitored by neck CT, chest CT, abdominal CT,
endoscopy, and air contrast oesophagography every 4–5 weeks.
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For measurable lesions, the response was assessed using the World
Health Organization criteria. Briefly, a complete response (CR) was
defined as the complete disappearance of all measurable and
assessable disease for at least 4 weeks. A partial response (PR) was
defined as more than 50% reduction in the sum of the products of
the longest perpendicular diameter of measurable disease for a
period of at least 4 weeks. Stable disease (SD) was defined as the
failure to observe CR, PR, or progressive disease for at least 4
weeks. Progressive disease (PD) was defined as a more than 25%
increase in the sum of the products of the longest perpendicular
diameter of measurable disease or the appearance of new lesions.
To investigate the changes in the grade of dysphagia, the response
of the primary tumour was evaluated using modified criteria of the
Japanese Society for Esophageal Diseases (1992). For primary
tumours, CR was defined as when all visible tumours, including
ulceration, disappeared for at least 4 weeks, confirmed by normal
endoscopic biopsy specimens. PR represented more than 50%
reduction in the area of the primary tumour as observed on
oesophagography. PD was considered to be an increase in the area
of the tumour of more than 25%. The response was evaluated by
oesophagography, oesophagoscopy, and neck, chest and abdom-
inal CT scans during each course.
Toxicity was evaluated using the criteria defined by the National
Cancer Institute Common Toxicity Criteria (NCI-CTC, version
2.0). Toxicity was assessed on a weekly basis during chemo-
radiotherapy and then biweekly during the subsequent chemo-
therapy.
The grade of dysphagia was determined by the dysphagia score
as described previously (Mellow et al, 1985; Knyrim et al, 1993). A
score of 0 denoted the ability to eat a normal diet, 1 denoted the
ability to eat some solid food, 2 denoted the ability to eat semi-
solids only, 3 denoted the ability to swallow liquids only, and 4
denoted complete dysphagia, even to saliva. Improvement of
dysphagia was defined as a decrease in the dysphagia score by at
least 1 point. Furthermore, we also used the PS score to evaluate
any improvement/deterioration of quality of life in patients under
treatment. The PS and dysphagia scores were recorded biweekly by
the physician during and after these treatments.
Statistical analysis
Follow-up evaluations after chemoradiotherapy were performed
every 3 months for the first 2 years and every 6 months thereafter
by endoscopy and CT scan. Differences between the two groups
were calculated by the w
2 test or the Wilcoxon rank-sum test.
Survival was calculated from the data at the initiation of treatment
by the actuarial Kaplan–Meier method (Kaplan et al, 1958).
Survival differences between the two groups were assessed by the
log-rank test. Multivariate analyses were performed using multiple
logistic regression. P-values of less than 0.05 were considered
significant.
RESULTS
Patient characteristics
The characteristics of the participating 57 patients are listed in
Table 1. Of these, 47 patients were men and 10 were women, and
the median age was 64 years. Most patients had a good
performance status. According to our criteria, the clinical staging
was classified as follows: stage II in four patients, stage III in 38,
and stage IV in 15. There were 22 patients (39%) with T3 disease,
and 35 (61%) with T4 disease. Of 57 patients, 15 (26%) had M1
LYM disease. Clinically involved sites in the 35 cases with T4
disease were thoracic aorta (20 patients), tracheobronchial tree (13
patients), and both sites (2 patients). A single patient had cervical
node metastasis, 12 had abdominal nodes, and two had metastases
in both nodes. Most (90%) of the primary tumours were more than
5cm long, with a median length of 7cm (range, 4–15cm). All 57
patients had histopathologically confirmed squamous cell carci-
noma. In all, 53 patients (93%) completed at least the chemo-
radiotherapy segment with a total radiation dose of 60Gy. The
remaining four patients did not complete chemoradiotherapy; two
experienced disease progression and two died because of
treatment-related oesophagoaortic fistula. Of the 53 patients with
complete chemoradiotherapay segment, eight and 22 patients had
a 1-week break and a 2-week break after a 3-week treatment,
respectively. The remaining 23 patients had an interruption during
chemoradiotherapy. Of the 46 patients who responded to
chemoradiotherapy, 40 (87%) received the additional two or more
courses of chemotherapy. However, six patients completed only
one course of chemotherapy, because these six patients achieved a
CR after one course of chemotherapy.
According to the 1983 AJCC criteria, the clinical staging was
classified as follows: stage II in none, stage III in 50 patients, and
stage IV in seven. There were 32 patients (56%) with T3 disease,
and 25 (44%) with T4 disease in AJCC criteria. None of the patients
was classified as T2 disease since all patients had dysphagia. Of the
57 patients, T4 disease was predominant in our criteria; however,
T3 disease was predominant in AJCC criteria. The frequency of T3
and T4 disease based on our criteria was not significantly different
from that in AJCC criteria (P¼0.0607). In contrast, 26% of 57
patients had M1 LYM disease based on our criteria; whereas 12%
had M1 LYM based on AJCC criteria alone. There was no
significant difference between the two groups (P¼0.0576). Four
patients were classified as stage II (T3N0M0) based on our criteria;
however, none of the patients had stage II based on AJCC criteria
and all patients were classified as stage III or IV.
Clinical response to chemoradiotherapy
The results of the overall response are summarised in Table 2. Of
the 57 eligible patients, 24 (42%) achieved CR. In all, 46 patients,
including the 24 CR cases, demonstrated an objective response
according to the Japanese evaluation criteria, which resulted in a
response rate of 81%. Nine patients showed an SD, and two had a
PD. The CR rate was significantly lower in patients with T4 (10 of
Table 1 Patient characteristics
No. of patients 57
Sex (male / female) 47/10
Age (range) 64 (45–75 years)
Performance status
04 1
11 5
21
Median tumour length (range) 7.0 (4–15cm)
Location
a
Upper 11
Middle 31
Lower 15
Histopathology
Well differentiated 6
Moderately differentiated 41
Poorly differentiated 10
Stage (UICC)
T3 M0 18
T3 M1 4
T4 M0 24
T4 M1 11
aLocation of the tumour according to the TNM classification; UICC: International
Union Against Cancer.
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Furthermore, the CR rate in patients with M1 LYM (4 of 15; 27%)
disease was not significantly different from that in patients with
M0 LYM (20 of 42; 48%, P¼0.2663). In 15 patients with M1 LYM
disease, the CR rate in those with cervical node metastasis was not
significantly different from that in patients with abdominal node
metastasis. Of 11 patients with T4M1 disease, two (18%) achieved a
CR and one (9%) had over 3-year survival. In multivariate
analyses, the CR rate based on our criteria was related to T factor
(P¼0.0351), but not to M factor (P¼0.4413). In contrast, the CR
rate based on AJCC criteria did not correlate with the T
(P¼0.0535) or M factor (P¼0.6805).
Toxicity
The major side effects of chemoradiotherapy encountered in our
patients during treatment are listed in Table 3. These included
myelosuppression and oesophagitis. Grade 3 and higher leukocyto-
penia, anaemia, thrombocytopenia, and oesophagitis occurred in
30, 33, 14, and 25% of the patients, respectively. Two patients (4%)
developed sepsis associated with leukocytopenia; however, these
patients recovered from sepsis with the use of filgrastim and
antibiotics. Of 35 patients with T4 disease, three (9%) developed
treatment-related perforation of the oesophageal wall: one devel-
oped a mediastinal fistula, while each of the other two developed
an aortic fistula. These three patients had T4 disease before
treatment, and these events occurred during chemoradiation. One
patient showed spontaneous healing of the mediastinal fistula after
the disappearance of inflammatory findings, despite continuation
of treatment, and achieved a PR. The remaining two patients with
oesophagoaortic fistulae died of massive bleeding during two
courses and four courses of chemoradiation, respectively. Nausea
was not associated with chemoradiotherapy for patients with
abdominal metastatic nodes.
Treatment was interrupted during the chemoradiotherapy
segment in 23 patients for the following reasons: persistent
leukocytopenia (n¼17), fistula (n¼3), and other complications
(n¼3). The median duration of the interruption because of
persistent leukocytopenia was 6 days (1–13 days) after a definite
break. All 17 patients could pursue the treatment. There were two
(4%) deaths related to treatment: as a result of oesophagoaortic
fistula, as mentioned above. However, the patient with mediastinal
fistula continued the treatment after a 1-week interruption, since
inflammation could be improved with the use of antibiotics. In all
patients, treatment had little effect on body weight ( 1.379.2%).
Late radiation-related complications included pneumonitis and
pericarditis. Pneumonitis of grade 2 or less occurred in 16 patients
(28%), but none of the patients developed grade 3 or higher
toxicity. Pneumonitis occurred at a median of 5.5 months from the
end of radiotherapy (range, 3–8 months). Grade 3 pericarditis
with pericardial effusion was detected in one patient (2%).
Dyspnoea owing to pericardial effusion appeared after approxi-
mately 6 months from the end of radiotherapy. Histopathologi-
cally, no malignant cells were found in pericardial effusion
samples. This patient remains disease-free and is still alive after
more than 3 years of termination of treatment.
Grade of dysphagia
Table 4 summarises the effects of treatment on the dysphagia
score. Most patients had severe dysphagia caused by oesophageal
carcinoma. With regard to the primary lesions as evaluated by the
Japanese criteria, 47 (83%) of the 57 patients showed improvement
of the dysphagia score, including 25 (44%) with CR. These 25 CR
cases became dysphagia-free, and 11 (44%) never complained of
dysphagia over a 3-year period. Of the remaining 13 patients,
dysphagia appeared again after treatment in eight, which was
because of local recurrence in five, and compression of metastatic
lymph node in three. Implantation of a self-expanding metallic
stent was performed in these patients, because these eight patients
developed dysphagia caused by malignant stricture after failure of
chemoradiotherapy.
The dysphagia score decreased from 3.2 to 1.1 (Po0.0001), and
dysphagia improved in 46 (81%) of the 57 patients. Of the 47
patients in whom the primary lesion responded to chemoradio-
therapy, dysphagia improved in 46, while one patient could not
take solid food because of a progressive oesophageal stricture
induced by radiation-related fibrotic changes. Of these 46 patients,
dysphagia improved in 27 (59%) following a single course of
chemoradiotherapy, and in 19 (41%) after two courses. The
median duration of dysphagia improvement was 10 months after
treatment in these patients. The proportion of PS 0, 1, 2, and 3
before treatment was 41 (72%), 15 (26%), 1 (2%), and 0 (0%),
Table 2 Response results
CR PR SD PD
Number of patients n%n%n%n %
Primary tumour 57 25 44 22 39 10 17 0 0
Overall 57 25 42 22 39 9 16 2 3
CR=complete response; PR=partial response; SD=stable disease; PD=progressive
disease.
Table 3 Major complications appearing during and after chemoradio-
therapy
Grade 1 Grade 2 Grade 3 Grade 4
n%n%n% n %
Leukocytopenia 11 19 23 40 14 25 3 5
Anaemia 3 5 22 39 19 33 0 0
Thrombocytopenia 5 9 6 11 5 9 3 5
Nausea/Vomiting 17 30 5 9 9 16 0 0
Diarrhoea 5 9 11 19 5 9 2 4
Mucositis 6 11 6 11 5 9 0 0
Oesophagitis 23 40 11 19 9 16 5 9
Renal 5 9 11 19 0 0 0 0
Pulmonary
a 1 1 1 95900 0 0
Cardiac
a 006 1 112 0 0
aLate radiation-related complications.
Table 4 Dysphagia score before and after concurrent chemoradio-
therapy
Before treatment After treatment
Dysphagia score n% n %
Grade 0 0 0 24 42
Grade 1 0 0 16 28
Grade 2 6 10 8 14
Grade 3 36 65 7 12
Grade 4 15 25 2 4
A score of 0 denotes the ability to eat a normal diet, 1 denotes the ability to eat some
solid food, 2 denotes the ability to eat semisolids only, 3 denotes the ability to
swallow liquids only, and 4 denotes complete dysphagia, even to saliva.
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37 (65%), 16 (28%), 3 (5%), and 1 (2%), respectively. The PS was
still 2 or 3 after treatment in some patients with progressive
disease; however, most patients had a PS before and after
treatment.
Survival
After a median follow-up period of 14 months (range, 1–58
months), 17 (30%) patients were still alive. Survival rates of 1 and 3
years were 61% (35 of 57) and 19% (11 of 57), respectively. Figure 1
shows the survival curves of 57 patients based on the T factor (T3
or T4). The median survival times of 22 patients with T3 disease
and 35 patients with T4 disease were 29 and 11 months,
respectively; the survival rate of patients with T3 disease was
significantly longer than that of patients with T4 disease
(P¼0.001, log-rank test). Furthermore, when the patients were
divided into two subgroups of 15 with M1 LYM (four patients with
T3 and 11 with T4) and 42 with M0 LYM (18 patients with T3 and
24 with T4), the median survival time of 42 patients with M0
disease (15 months) was not different from that of 15 patients with
M1 disease (12 months, P¼0.3545, log-rank test). Multivariate
analyses showed that the survival rate based on our criteria was
strongly related to T factor (P¼0.0051), but not to M factor
(P¼0.4615). In contrast, the proportion of T3 and T4 disease or
M0 and M1 disease classified based on our criteria was not similar
to that classified by AJCC criteria, although the survival rate based
on the AJCC criteria was also related to the T factor (P¼0.0247)
but not to the M factor (P¼0.5128) in multiple logistic regression
(see Figure 2).
DISCUSSION
The value of chemoradiotherapy for the treatment of unresectable
oesophageal carcinoma remains controversial, and only a few
clinical studies have been published since the 1980s (Leichman
et al, 1984; Leichman et al, 1987; Poplin et al, 1987; Coia et al, 1991;
Herskovic et al, 1992; Frorastiere et al, 1993; Poplin et al, 1994).
Most patients in these studies had local–regional disease (UICC
stage I or II). Although some reports included patients with T4
disease, the proportion of such patients was usually low and the
clinical outcomes were not clearly described. The results of these
studies, including CR rates and survival rates, were confusing,
since the clinical and pathological backgrounds varied, especially
with regard to the stage of the disease. Therefore, stratification by
clinical stage should be applied when evaluating the impact of
treatment on survival and response. Coia et al (1991) reported
long-term results with 5-FU and mitomycin C chemotherapy
combined with radiation therapy. In their study, 33 patients with
stage III and IV disease were treated with chemotherapy and 50Gy
of radiation therapy with palliative intent; this treatment resulted
in a median survival duration of 9 months and a 2-year survival
rate of only 3% (Coia, 1994). Zeone et al (1992) reported the results
of curative nonsurgical treatment that consisted of 5-FU, CDDP,
and 64Gy of radiotherapy combined with neodymium: yttrium-
aluminium garnet (Nd:YAG) laser therapy in appropriate patients.
They treated 65 patients who had predominantly T1–3 disease,
but their study included five patients with T4 disease. Although the
3-year survival rate of the 65 eligible patients was 37%, all five
patients with T4 disease died within 18 months. In another large
study from Australia, 79 patients with advanced-stage carcinoma,
including 25 with systemic metastasis, were treated with 5-FU,
CDDP, and 30–35Gy of radiation therapy (Burmeister et al, 1995).
A 3-year survival rate of 9% was achieved in patients with
advanced disease. However, clinical stages based on the TNM
classification were not described; therefore, the stage at which
patients survived longer is unknown. A literature search produced
no other studies that specifically investigated chemoradiotherapy
for locally advanced disease, such as T4 and/or M1 LYM. In our
previous study, a CR rate of 33% and a 3-year survival rate of 23%
were achieved in patients with unresectable T4 tumours and/or M1
LYM disease (Ohtsu et al, 1999), suggesting that concurrent
chemoradiotherapy was potentially curative for locally advanced
carcinoma. In our present study, a CR rate of 39% and a 3-year
survival rate of 19% were achieved in patients with ‘severe
dysphagia’ accompanied by T3 or T4 disease.
With regard to the efficacy and feasibility of chemoradiotherapy,
our clinical outcomes in the present study were similar to those in
our previous multicentre study. In our previous and present
studies, the extended field of irradiation was used to cover the
three field dissected areas by extended surgery in Japan.
Furthermore, a combination of 5-FU and CDDP has become a
standard regimen because of the synergism between the two agents
and their radiosensitising effects (Douple et al, 1980; Scanlon et al,
1986; Byfield, 1990).
Some studies of a continuous irradiation course combined with
5-FU and CDDP indicated that grade 3 and higher leukocytopenia
and oesophagitis occurred in 33–54% and 48–50% of patients,
respectively (Herskovic et al, 1992; Poplin et al, 1994). It is likely
that severe leukocytopenia and oesophagitis frequently occurred in
a continuous irradiation course. Since the presence of severe
toxicity because of both the extended field of irradiation and a
combination of chemoradiotherapy had been expected, we used a
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Figure 1 Survival curves of 22 patients with T3 disease and 35 patients
with T4 disease.
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with M1 LYM disease.
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period instead of using a continuous irradiation course. In
contrast, the periods of recovery from toxicity were not sufficient
for a 1-week break in many patients. Therefore, we believed that at
least a 2-week break would be required to administer chemo-
radiotherapy without an interruption. Our results suggested that
definitive chemoradiotherapy with a split course radiation
technique accompanied by a 2-week break is feasible for locally
advanced carcinoma.
In contrast, our results were associated with significant toxicity,
consisting predominantly of leukocytopenia and perforation of the
oesophageal wall. The high incidence of leukocytopenia and
oesophagitis might be because of both the extended field of
irradiation and combination of chemoradiotherapy. Fortunately,
the leukocytopenia was not a fatal complication, and patients with
leukocytopenia-related sepsis could recover with the use of
filgrastim and antibiotics. Perforation of the oesophageal wall
was an unavoidable significant toxic effect of treatment for T4
disease. However, no perforation occurred in patients with T3
disease. Previous studies reported the development of fistula in
29% of 94 patients with oesophagobronchial involvement who
were treated with radiation therapy alone (Roussel et al, 1995).
Early death occurred in all patients who developed complications,
with a median period of 1.7 months. The rate of oesophageal
perforation in the present study was 9% (three of 35 patients) in
patients with T4 disease, which was lower than that reported by
Roussel et al. Furthermore, one of the three perforations in our
study closed spontaneously following additional chemoradio-
therapy after improvement of the inflammatory process, and the
patient achieved PR with respect to the primary tumour. Insertion
of the metallic stent as a palliative treatment was not performed in
our patients despite perforation of the oesophageal wall. However,
these results do not support the criticism that chemoradiotherapy
should be contraindicated for T4 disease, especially in cases that
involve fistula.
In contrast, several reports have proposed that insertion of a
metallic stent is effective in the palliative treatment of malignant
oesophageal stricture (Song et al, 1991; Bethge et al, 1992; Fleischer
et al, 1992; Kozarek et al, 1992; Schaer et al, 1992; Knyrim et al,
1993; May et al, 1995; Wengrower et al, 1998). However, the
indication for metallic stent insertion in patients with malignant
stricture caused by oesophageal carcinoma remains controversial.
In one study, 21 patients with malignant oesophageal stricture
received a self-expanding metallic stent, and all stents were placed
successfully with no immediate severe complications (Knyrim et al,
1993). Dysphagia improved in 92% of their patients and the
dysphagia score decreased from 3 to 1, while the mean survival
time was 168 days. In another study, 30 patients with incurable
malignant obstruction of the oesophagus and cardia were treated
with self-expanding metallic stents (May et al, 1995). All stents
were placed successfully with no early complications. Dysphagia
improved in 83% of the patients within 1 week, and the mean
survival time was 108 days (range, 14–211 days). In a multicentre
study from Israel, 81 patients with malignant obstruction of the
oesophagus and gastric cardia were treated with self-expanding
metallic coils (Wengrower et al, 1998). All coils were placed
successfully and dysphagia improved in 96% of the patients, while
the dysphagia score dropped from 3.5 to 1.2. The mean survival
time was 16 weeks (range, 4–56 weeks). In these results (Knyrim
et al, 1993; May et al, 1995; Wengrower et al, 1998), the stent was
placed successfully and dysphagia improved in approximately 90%
of the patients. Furthermore, there seemed to be few fatal
complications in the early postinsertion period, although late
complications occurred in 22–30% of the patients (Knyrim et al,
1993; May et al, 1995; Wengrower et al, 1998). The mean survival
time was 4–5 months after stent insertion. Efficacy, complications,
and survival time are not likely to be different, although different
stents are inserted as an initially palliative treatment. Approxi-
mately 90% of our patients had severe dysphagia before
chemoradiotherapy, however, dysphagia improved in 81% of the
patients and the average dysphagia score decreased from 3.1 to 1.1.
Most of our patients had a good PS before and after treatment. The
change in the grade of dysphagia in our study was not different
from those reported by other investigators (Knyrim et al, 1993;
May et al, 1995; Wengrower et al, 1998). However, implantation of
the metallic stent is unlikely to be curative in patients with severe
dysphagia. In contrast, most patients with T3 disease become
dysphagia-free following such a procedure. If a metallic stent is
initially inserted for patients with severe dysphagia, such patients,
especially those with T3 disease, are unlikely to have a complete
cure. Assessment of the clinical stage according to the TNM
classification should be performed in patients with dysphagia
caused by advanced oesophageal carcinoma, and chemoradiother-
apy should be provided to patients with T3 or T4 accompanied by
M1 LYM disease. Insertion of a metallic stent as a palliative
treatment may be of limited value, for example, to patients with
oesophageal fistula or systemic metastasis, or those who develop
stricture after failure of the primary curative treatment (Kaneko
et al, 2002).
The development of imaging techniques such as CT scan,
magnetic resonance imaging, and endoscopic ultrasonography, has
allowed a more accurate clinical staging of oesophageal tumours in
recent years. These advances in diagnostic procedures have
allowed the selection of optimal treatment modality through
clinical staging. Although there are some ‘grey zones’ with respect
to determining T3 or T4 disease by imaging, several studies have
reported the successful use of CT scans and/or magnetic resonance
imaging with an accuracy rate of X80% (Picus et al, 1983;
Takashima et al, 1991). We adopted their reported criterion to
define T3 or T4 disease. Diagnostic radiologists, together with
medical oncologists, were responsible for the final staging. With
regard to the determination of positive nodes, there are no reliable
diagnostic staging criteria to date. Therefore, we used the 1-cm size
to indicate a positive node. The positive predictive value of this
criterion was only 50% in the study of Curtin et al (1998). This low
value might explain our good results in cases with M1 LYM
disease, although all 15 patients with M1 LYM disease had
advanced T3 or T4 disease with severe stricture. Moreover, the
patients classified with T3M0 and T4M0 disease would have had
occult nodal involvement that was not detected by CT scan. Since
the survival rate in patients with M0 disease did not differ
significantly from that of patients with M1 LYM disease
(P¼0.3545), it is likely that any attempt to separate these groups
would be rather artificial. In contrast, only 11% of patients had an
EUS to define the depth of wall penetration to establish T3 disease.
Since our staging criteria for T3 disease used before treatment is
not standard, the clinical staging was also performed according to
1983 AJCC staging criteria. The proportions of T3 and T4 based on
the AJCC criteria were not similar to that based on our criteria,
although no significant differences were noted between the two
groups. However, our results suggested that the survival rate was
significantly related to T factor in multivariate analyses, when the
clinical staging is classified according to either our criteria or AJCC
criteria. The prior staging systems (1983 AJCC) were based on
clinical information, and the system may remain an important
prognostic indicator for patients managed with chemoradiation.
Literature search did not find other reports that recommended
chemoradiotherapy for locally advanced carcinoma with severe
stricture. In the present retrospective study, we investigated the
efficacy and feasibility of concurrent chemoradiotherapy for
patients with severe dysphagia caused by advanced oesophageal
squamous cell carcinomas of T3 or T4 and M1 LYM disease. Our
results, especially with regard to long-term survival, allow us to
suggest that definitive chemoradiotherapy is potentially curative
for locally advanced oesophageal carcinoma defined by clinical
imaging. Thus, proper clinical staging before treatment is
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carcinoma, since the efficacy of such treatment correlates with the
T factor. Treatment-related fatal complications can occur in
patients with T4 disease; however, toxicities including late
radiation-related complications were manageable. Further investi-
gation of the combined treatment modality as a curative approach
is required particularly for cases with locally advanced oesophageal
carcinoma with T4 disease.
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